A prescription form of CBD is approved for treating seizure disorders (such as epilepsy). While CBD is also used for conditions like anxiety, pain, dystonia (a muscle disorder), Parkinson's disease, Crohn's disease, and more, there is insufficient scientific evidence to support its effectiveness for these uses. In 2018, laws were passed that legalized the sale […]
Jan 08, 2025
"Wishing all our valued partners, clients, and colleagues a Merry Christmas and a joyful holiday season from the VPLUS team! May the new year bring success, growth, and continued collaboration."
Dec 18, 2024
The lung’s delicate surfactant layer is of critical importance to the organ’s overall physiology and innate immune function. Both alveolar type II cells and alveolar macrophages are the principal subsets that maintain and catabolize surfactant at the liquid-air interface. Our study reveals that ENDS exposure disrupts both the lipid and protein components of pulmonary surfactant, […]
Dec 12, 2024
Neurodegenerative diseases leading to Parkinson's disease (PD) and Alzheimer's disease (AD) have become a major global health burden. Current treatments are mainly aimed at controlling symptoms, and there are no effective treatments in clinical practice to prevent neurodegeneration or induce neuronal repair. Therefore, the need for new research on these two diseases is urgent. The […]
Dec 05, 2024
Sativex® (nabiximols) is an oromucosal cannabinoid drug that contains 2.7 mg THC and 2.5 mg CBD per spray. It has been approved by regulators in 29 countries for the treatment of spasticity in multiple sclerosis. The medical application of cannabis began very early. From the mid-19th century to the 20th century, it was used by […]
Nov 26, 2024